

Fred D Lublin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/345539/publications.pdf>

Version: 2024-02-01

90
papers

20,542
citations

172457

29
h-index

51608

86
g-index

91
all docs

91
docs citations

91
times ranked

15528
citing authors

#	ARTICLE	IF	CITATIONS
1	Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasma. <i>Brain</i> , 2022, 145, 569-583.	7.6	40
2	CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 608-619.	3.0	13
3	Confirming a Historical Diagnosis of Multiple Sclerosis. <i>Neurology: Clinical Practice</i> , 2022, 12, 263-269.	1.6	4
4	How patients with multiple sclerosis acquire disability. <i>Brain</i> , 2022, 145, 3147-3161.	7.6	126
5	Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 62, 103737.	2.0	13
6	Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 1106-1116.	3.3	1
7	Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1276-1283.	3.0	10
8	Hippocampal volume is more related to patient-reported memory than objective memory performance in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 568-578.	3.0	6
9	Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102715.	2.0	3
10	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study. <i>JAMA Neurology</i> , 2021, 78, 558.	9.0	132
11	Sleep disturbance and memory dysfunction in early multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1172-1182.	3.7	7
12	Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e1560-e1570.	1.1	19
13	Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. <i>Neurology</i> , 2021, 97, e1334-e1342.	1.1	12
14	Dietary factors and MRI metrics in early Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103031.	2.0	13
15	Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103229.	2.0	16
16	Cerebellar pathology and disability worsening in relapsing-remitting multiple sclerosis: a retrospective analysis from the CombiRx trial. <i>European Journal of Neurology</i> , 2021, 29, 515.	3.3	1
17	Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1247-1255.	3.0	35
18	Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1111-1120.	3.0	23

#	ARTICLE	IF	CITATIONS
19	Real-world studies provide reliable comparisons of disease modifying therapies in MS – Commentary. Multiple Sclerosis Journal, 2020, 26, 163-164.	3.0	0
20	Deep Learning-Based Neural Tissue Segmentation of MRI in Multiple Sclerosis: Effect of Training Set Size. Journal of Magnetic Resonance Imaging, 2020, 51, 1487-1496.	3.4	31
21	Deep Learning for Predicting Enhancing Lesions in Multiple Sclerosis from Noncontrast MRI. Radiology, 2020, 294, 398-404.	7.3	67
22	Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1752-1764.	3.0	34
23	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991.	1.1	6
24	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	10.2	64
25	Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642096901.	3.5	20
26	The 2013 clinical course descriptors for multiple sclerosis. Neurology, 2020, 94, 1088-1092.	1.1	73
27	A clinically feasible 7-Tesla protocol for the identification of cortical lesions in Multiple Sclerosis. European Radiology, 2020, 30, 4586-4594.	4.5	18
28	Detection of subtle gait disturbance and future fall risk in early multiple sclerosis. Neurology, 2020, 94, e1395-e1406.	1.1	25
29	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. Neurology, 2020, 95, e1027-e1040.	1.1	28
30	Early complement genes are associated with visual system degeneration in multiple sclerosis. Brain, 2019, 142, 2722-2736.	7.6	30
31	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet, The, 2019, 394, 1352-1363.	13.7	433
32	Lymphocyte counts and infection rates. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	7
33	Open-label, add-on trial of cetirizine for neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e441.	6.0	22
34	Clinical Course of Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a028928.	6.2	186
35	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	10.2	4,605
36	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876064.	1.0	32

#	ARTICLE	IF	CITATIONS
37	Brain microstructural injury occurs in patients with RRMS despite "no evidence of disease activity"™. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 977-982.	1.9	16
38	The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. Multiple Sclerosis Journal, 2018, 24, 1469-1484.	3.0	41
39	061"Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A25.2-A25.	1.9	5
40	Objective and subjective measures of dalfampridine efficacy in clinical practice. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731878674.	1.0	3
41	"Location, location, location" Multiple Sclerosis Journal, 2018, 24, 1396-1398.	3.0	8
42	Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions?. Multiple Sclerosis Journal, 2017, 23, 43-50.	3.0	40
43	Synchronization and variability imbalance underlie cognitive impairment in primary-progressive multiple sclerosis. Scientific Reports, 2017, 7, 46411.	3.3	27
44	The "Field Hypothesis"™: rebound activity after stopping disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2017, 15, A1-A2.	2.0	13
45	Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note. Multiple Sclerosis Journal, 2017, 23, 982-987.	3.0	7
46	A composite measure to explore visual disability in primary progressive multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731770962.	1.0	3
47	Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years. Multiple Sclerosis and Related Disorders, 2017, 18, 95-102.	2.0	15
48	The relationship between cortical lesions and periventricular NAWM abnormalities suggests a shared mechanism of injury in primary-progressive MS. NeuroImage: Clinical, 2017, 16, 111-115.	2.7	12
49	PO128"Infusion-related reactions with ocrelizumab in rms and ppms. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A46.1-A46.	1.9	0
50	Cerebellar lobule atrophy and disability in progressive MS. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1065-1072.	1.9	47
51	PO129"Neda analysis by epoch in the opera studies of ocrelizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A46.2-A46.	1.9	3
52	Cerebellar volume as imaging outcome in progressive multiple sclerosis. PLoS ONE, 2017, 12, e0176519.	2.5	19
53	Relationship between timed 25-foot walk and diffusion tensor imaging in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731665536.	1.0	7
54	Diagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and Space. Current Neurology and Neuroscience Reports, 2016, 16, 90.	4.2	25

#	ARTICLE	IF	CITATIONS
55	Multiple Sclerosis and Other Inflammatory Diseases. , 2016, , 249-258.		0
56	Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis. Journal of Neurology, 2016, 263, 354-360.	3.6	30
57	William Austin Sibley, MD (1925â€“2015). Multiple Sclerosis Journal, 2016, 22, 11-12.	3.0	1
58	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, The, 2016, 387, 1075-1084.	13.7	379
59	Novel Agents for Relapsing Forms of Multiple Sclerosis. Annual Review of Medicine, 2016, 67, 309-321.	12.2	35
60	Relapses in multiple sclerosis: Relationship to disability. Multiple Sclerosis and Related Disorders, 2016, 6, 10-20.	2.0	36
61	Optic neuropathy in late-onset neurodegenerative ChÃ©diakâ€“Higashi syndrome. British Journal of Ophthalmology, 2016, 100, 704-707.	3.9	5
62	Effect of inâ€“painting on cortical thickness measurements in multiple sclerosis: A large cohort study. Human Brain Mapping, 2015, 36, 3749-3760.	3.6	15
63	Regional gray matter atrophy in relapsing remitting multiple sclerosis: Baseline analysis of multi-center data. Multiple Sclerosis and Related Disorders, 2015, 4, 124-136.	2.0	31
64	Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. Brain, 2015, 138, 517-539.	7.6	41
65	Association of Deep Gray Matter Damage With Cortical and Spinal Cord Degeneration in Primary Progressive Multiple Sclerosis. JAMA Neurology, 2015, 72, 1466.	9.0	32
66	Emergency Medical Care of Multiple Sclerosis Patients: Primary Data from the Mount Sinai Resource		

#	ARTICLE	IF	CITATIONS
73	Randomized study combining interferon and glatiramer acetate in multiple sclerosis. <i>Annals of Neurology</i> , 2013, 73, 327-340.	5.3	182
74	Editorial. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 153.	2.0	0
75	MS as a gateway disease. <i>Journal of the Neurological Sciences</i> , 2013, 333, 73-75.	0.6	1
76	Disease activity free status in MS. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 6-7.	2.0	43
77	Multiple Sclerosis as a Model Neurologic Disease. <i>Mount Sinai Journal of Medicine</i> , 2011, 78, 159-160.	1.9	0
78	Relapses do not matter in relation to long-term disability: No (they do). <i>Multiple Sclerosis Journal</i> , 2011, 17, 1415-1416.	3.0	15
79	The incomplete nature of multiple sclerosis relapse resolution. <i>Journal of the Neurological Sciences</i> , 2007, 256, S14-S18.	0.6	26
80	History of modern multiple sclerosis therapy. <i>Journal of Neurology</i> , 2005, 252, iii3-iii9.	3.6	46
81	Multiple sclerosis trial designs for the 21st century: Building on recent lessons. <i>Journal of Neurology</i> , 2005, 252, v46-v53.	3.6	18
82	Clinical features and diagnosis of multiple sclerosis. <i>Neurologic Clinics</i> , 2005, 23, 1-15.	1.8	82
83	Magnetic Resonance Imaging of Meningoradiculomyelitis in Early Disseminated Lyme Disease. <i>Journal of Neuroimaging</i> , 2003, 13, 264-268.	2.0	13
84	Effect of relapses on development of residual deficit in multiple sclerosis. <i>Neurology</i> , 2003, 61, 1528-1532.	1.1	394
85	When marketing and science intersect. <i>Neurology</i> , 2002, 59, 1480-1481.	1.1	15
86	The diagnosis of multiple sclerosis. <i>Current Opinion in Neurology</i> , 2002, 15, 253-256.	3.6	15
87	Spectrum and classification of inflammatory demyelinating diseases of the central nervous system. <i>Current Neurology and Neuroscience Reports</i> , 2001, 1, 249-256.	4.2	8
88	Placebo-controlled clinical trials in multiple sclerosis: Ethical considerations. <i>Annals of Neurology</i> , 2001, 49, 677-681.	5.3	52
89	Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. <i>Annals of Neurology</i> , 2001, 50, 121-127.	5.3	6,122
90	Placebo-controlled clinical trials in multiple sclerosis: Ethical considerations. <i>Annals of Neurology</i> , 2001, 49, 677-681.	5.3	3